Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK0803, lovastatin · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| MK0803, lovastatin | DRUG | - |
| Self-Management System | BEHAVIORAL | - |
Inclusion Criteria: * Must be able to read and understand English without assistance. * For Males: Minimum age 45 years and Maximum age N/A (No limit). * For Females: Minimum age 55 years and Maximum age N/A (No limit). Exclusion Criteria: * Pregnant or nursing * Drug allergy
MK0803 is an investigational small molecule being studied for the treatment of hypercholesterolemia, a condition characterized by high levels of cholesterol in the blood. It is being developed as a potential therapeutic option for patients with this metabolic disorder.
MK0803 is a small molecule developed for hypercholesterolemia. As a small molecule, it is designed to interact with specific biological pathways involved in cholesterol metabolism, though its precise molecular target has not been disclosed in available information.
MK0803 is being developed by Merck & Company, Inc., a global pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. Merck is conducting clinical research to evaluate the safety and efficacy of this investigational drug.
MK0803 is currently in Phase 3 clinical development. It has completed one Phase 3 trial, which was a six-month consumer behavior study of a self-management system. The drug remains investigational and has not yet been approved by regulatory authorities.
MK0803 has been studied in one completed Phase 3 clinical trial with the identifier NCT00092846. This trial, titled 'A 6-Month Consumer Behavior Study of a Self-Management System (0803-084)', enrolled 1000 participants with hypercholesterolemia and was completed.
Yes, MK0803 is also known as lovastatin. Lovastatin is a well-known statin medication used to lower cholesterol. The drug is being studied under the code name MK0803 in clinical trials for hypercholesterolemia.